Radar · Life Sciences in Durham
Best Life Sciences Companies in Durham, United States
The 192 best Life Sciences companies in Durham, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BioCryst.
By Riya SenguptaFinancials
192companies tracked
$4.8Bdisclosed funding
0unicorns
130have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × DURHAM
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
240kcombined LinkedIn audience
51%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Durham
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | BioCryst Developer of small molecule drugs for orphan & autoimmune diseases and antivirals | $867M | 54 mo ago | 536 536 → 615 (+15%) | 1986 | Jon Stonehouse CEO | — | 1 internship |
| 2 | Areteia Developer of therapeutics for eosinophilic asthma | $425M | 28 mo ago | 19 | 2022 | Jorge Bartolome CEO | — | — |
| 3 | Humacyte Provider of human tissue-based products for vascular disease | $425M | 62 mo ago | 70 70 → 166 (+137%) | 2004 | Juliana Blum Co-Founder | 137 patents Engineered vascular grafts and medicated implantable matrices for blood vessel replacement. | — |
| 4 | AskBio Developer of AAV technologies for treating genetic and complex disorders | $235M | 69 mo ago | 900 | 2001 | Jude Samulski Co-Founder & CSO | 75 patents AAV-based gene therapy vectors for kidney delivery and neurological disease treatment | 1 partnership · 1 award |
| 5 | GenetronHealth Provider of services in the development of precision medicine tools for cancer treatment | $191M | 78 mo ago | 993 | 2013 | Sizhen Wang Co-Founder & CEO | — | 1 launch |
| 6 | Argos Therapeutics RNA-based dendritic cell therapies for cancer and infectious diseases. | $170M | 108 mo ago | 120 | 1997 | — | 243 patents Immunotherapy platforms: dendritic cell vaccines, CD83 peptides, anti‑IFN‑α antibodies, cell processing. | — |
| 7 | Viamet Pharmaceuticals Innovation hub revolutionizing healthcare, education, safety, energy, and technology with AI | $161M | 116 mo ago | 13 | 2005 | Tom O'halloran Co-Founder | 395 patents Fluorinated heterocyclic antifungal agrochemicals and metalloenzyme inhibitor therapeutics. | — |
| 8 | Pairwise Provider of gene editing technology for climate-resilient, nutritious, and sustainable crops | $155M | 21 mo ago | 163 | 2017 | Tom Adams CEO | — | 1 internship · 1 partnership · 1 award |
| 9 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | 2006 | — | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 10 | StrideBio Developer of AAV based gene therapies for rare diseases | $98M | 63 mo ago | 109 | 2015 | — | 89 patents Recombinant adeno-associated virus vector production and gene‑therapy delivery systems. | — |
| 11 | Baebies Provider of diagnostic products for pediatrics | $94M | 9 mo ago | 133 133 → 73 (-45%) | 2013 | Richard West Co-Founder & CEO | 56 patents Rapid microfluidic PCR and point‑of‑care diagnostic platforms for biochemical assays | 3 launchs |
| 12 | Xilis Developer of drug discovery and precision therapy platform for oncology 53Patents top 21%Moat top 21%Innovation top 22%Funding top 26% All 9 signals ▾Patentstop 21% Moattop 21% Innovationtop 22% Fundingtop 26% Talentbottom 49% Marketbottom 46% Globalbottom 42% Techbottom 29% Newsbottom 22% Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $89M | 14 mo ago | 72 | 2019 | Hans Clevers Co-Founder | 97 patents Micro-organosphere generation, manipulation, and drug testing via advanced microfluidic platforms | — |
| 13 | Atsena Therapeutics Developer of gene therapies for the treatment of ocular diseases | $88M | 9 mo ago | 23 23 → 49 (+113%) | 2020 | Shannon Boye Founder & Director | — | 1 partnership |
| 14 | Aerami Developer of therapeutics to treat cardiopulmonary diseases | $58M | 31 mo ago | 17 | 2010 | — | — | — |
| 15 | Tellus Therapeutics Developer of therapeutic products to treat brain injury in children | $37M | 42 mo ago | 8 | 2018 | Eric Benner Co-Founder | — | — |
| 16 | 410 Medical Provider of rapid infusion system for critically ill patients | $37M | 15 mo ago | 33 | 2012 | Mark Piehl Co-Founder & CMO | — | — |
| 17 | T3D Therapeutics Developer of therapeutics for neurodegenerative diseases | $33M | 10 mo ago | 14 | 2013 | John Didsbury Founder and CEO | — | — |
| 18 | Polarean Imaging Developer of hyperloarized gas MRI for lung imaging | $31M | 24 mo ago | 28 28 → 29 (+4%) | 2012 | Bastiaan Driehuys Founder | — | — |
| 19 | Incyclix Bio A next-generation cell cycle control company advancing precision treatments for cancer 21Funding top 25%Talent top 28%Moat top 39%Tech bottom 31% All 6 signals ▾Fundingtop 25% Talenttop 28% Moattop 39% Techbottom 31% Globalbottom 29% Marketbottom 20% Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $30M | 2 mo ago | 6 | 2020 | Patrick Roberts Co-Founder & CEO | — | — |
| 20 | Levee Medical Developer of urological devices for post-prostatectomy | $27M | 4 mo ago | 3 | 2021 | Bruce Choi Founder & CTO | — | — |
| 21 | CytexOrtho Developer of bio-artificial devices to treat musculoskeletal diseases 32Funding top 38%Talent top 38%Growth top 41%Fin. health bottom 45% All 7 signals ▾Fundingtop 38% Talenttop 38% Growthtop 41% Fin. healthbottom 45% Techbottom 41% Globalbottom 32% Marketbottom 24% Funding: Raised $24.4M across 17 rounds · 17 rounds over 4 yrs (4.2/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $24M | 14 mo ago | 10 | 2006 | Frank Moutos Co-Founder | — | — |
| 22 | Opus Genetics Developer of gene therapies to treat retinal degenerative diseases 42Patents top 29%Funding top 30%Moat top 32%Innovation top 34% All 11 signals ▾Patentstop 29% Fundingtop 30% Moattop 32% Innovationtop 34% Talenttop 38% Growthtop 47% Techtop 50% Newstop 50% Globalbottom 36% Marketbottom 31% Fin. healthbottom 28% Patents: 26 patents matched (strict assignee match) · 26 filings since 2022 vs 0 in 2017-21 Funding: Raised $23.5M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 10 mo ago | 14 | 2021 | Jason Menzo Co-Founder | 26 patents Ophthalmic alpha‑adrenergic antagonist drugs for mydriasis, presbyopia, and AMD treatment | — |
| 23 | Reactive Biosciences Developer of boron-based medicines for various disease conditions | $23M | 16 mo ago | — | 2021 | Julie Grant CEO | — | — |
| 24 | Cell Microsystems Developer of a technology to isolate and recover single cells for molecular analysis | $19M | 33 mo ago | 28 | 2009 | — | — | — |
| 25 | GeneCentric Developer of diagnostics for cancer classification and treatment | $19M | 12 mo ago | 19 | 2011 | — | — | — |
| 26 | Ten63 Developer of therapeutics for undruggable targets 21Talent top 28%Funding top 32%Moat top 35%News top 44% All 7 signals ▾Talenttop 28% Fundingtop 32% Moattop 35% Newstop 44% Globalbottom 39% Techbottom 26% Marketbottom 24% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $18.3M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $18M | 3 mo ago | 10 | 2019 | Mark Hallen Co-Founder & CTO | — | — |
| 27 | Xemed Developing inhaled diagnostic agents for respiratory diseases using hyperpolarized gas MRI | $18M | 16 mo ago | 10 | 2004 | William Hersman Founder & CEO | 13 patents Patents concentrated in electrical & electronics | — |
| 28 | Cerulean Scientific Developer of an implantable medical devices for vascular patients | $14M | 11 mo ago | — | 2023 | Lora Allemeier CEO | — | — |
| 29 | Ascent Bio-Nano Technologies Innovating acoustofluidic technologies for research, diagnostics, and therapeutics with social impact | $14M | 9 mo ago | 2 | 2011 | Lin Wang Co-Founder & CEO | — | — |
| 30 | Deep Blue Medical Advance Developer of hernia mesh devices for treating hernia | $13M | 9 mo ago | 12 | 2015 | — | — | — |
| 31 | Inanovate Provider of multiplexed protein quantification platform for clinical diagnostics and research | $11M | 14 mo ago | 11 | 2006 | David Ure Chairman & Founder | 30 patents High-throughput immunoassay platforms for serology and cancer biomarker detection | — |
| 32 | Evecxia Therapeutics Developing 5-HTP drugs to amplify serotonin for mental illness treatment | $10M | 9 mo ago | 10 | 2013 | Marc Caron Co-Founder | — | — |
| 33 | Vascular BioSciences Vascular BioSciences: Pioneering targeted therapies, interventional devices, and molecular diagnostics | $8M | 14 mo ago | 24 | 1990 | David Mann CEO & Chairman | — | — |
| 34 | Lindy Biosciences Developer of formulation technology for bio-therapeutics drug delivery | $7M | 27 mo ago | 4 | 2016 | — | — | — |
| 35 | Celldom Developer of single cell analysis device | $6M | 14 mo ago | 9 | 2016 | Zachary Forbes Founder & CEO | 8 patents Microfluidic single-cell assay platforms for drug screening and barcoded particle analysis | — |
| 36 | Avicenna Provider of drug development solutions | $6M | 23 mo ago | — | 2020 | Pieter Burger Co-Founder | — | — |
| 37 | Altis Biosystems Provider of invitro platform for drug testing | $5M | 6 mo ago | 29 | 2015 | Scott Magness Co-Founder | — | — |
| 38 | EydisBio Developer of therapeutics for immunological disorders | $5M | 21 mo ago | 2 | 2016 | Timothy Haystead Co-Founder | — | — |
| 39 | Alleviate Health Provider of AI-powered platform for clinical research participant recruitment workflows | $4M | 8 mo ago | — | 2023 | Saathvik Boompelli Co-Founder | — | — |
| 40 | inSoma Bio Provider of protein-based biomaterials for tissue engineering and regenerative medicine | $3M | 6 mo ago | 6 | 2018 | Stefan Roberts Co-Founder & CEO | — | — |
| 41 | Reselute Developer of solutions for the treatment of orthopedic-related infections | $3M | 12 mo ago | 5 | 2022 | Jake Donovan Co-Founder and Head of Product Development | 3 patents Orthopedic intramedullary fixation devices with integrated drug‑eluting capabilities | — |
| 42 | Galaxy Diagnostics PCR-based Human and Animal testing for vector-borne diseases | $3M | 14 mo ago | 15 | 2009 | — | — | — |
| 43 | VQ Biomedical Developer of intravascular oxygenation catheter for respiratory failure in hospitals | $2M | 22 mo ago | — | 2023 | Marc Deshusses Co-Founder and Principal Scientist/Engineer | — | — |
| 44 | Regennova Developer of therapies restoring immune balance after infection or injury | $1M | 16 mo ago | — | 2021 | Michael Vitek Founder | 4 patents Antimicrobial peptide agents for crop protection and medical/animal therapeutic applications. | — |
| 45 | Arrevus Online platform providing slot games with potential rewards and trusted service | $1M | 13 mo ago | 4 | 2017 | — | 8 patents Antimicrobial peptide and fusidic acid formulations for treating bone, joint and skin infections | — |
| 46 | Drive Therapeutics Developer of aptamer-based therapies for retinal diseases | $1M | 11 mo ago | 3 | 2019 | Ryan Quick Co-Founder | — | — |
| 47 | Aestas Pharma Developer of diagnostic imaging and therapeutic agents for neurodegenerative diseases | $900K | 12 mo ago | — | 2016 | Zahed Subhan CEO | — | — |
| 48 | Avalo Developer of a platform for accelerated crop breeding and evolution | $250K | 15 mo ago | 10 | 2020 | Brendan Collins Co-Founder | 14 patents AI-driven bioinformatics platforms for genomic, gene‑environment and spectral data analysis | 1 partnership |
| 49 | AimMax Developer of therapies for treating infection, inflammation, and pain | $200K | 14 mo ago | 3 | 2017 | — | — | — |
Top 12 Life Sciences companies in Durham
#1
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Public · Durham, North Carolina · founded 2006 · 236 employees
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 19%Funding
top 21%Moat
top 32%Patents
top 36%News
top 38%Market
top 39%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 6/10 · IP moat: 68 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 10.1% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
Investors
NIST, NIH, North Carolina, Treasury, VenBio, Baxter
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#2
Series B · Durham, North Carolina · founded 2020 · 6 employees$30Mraised▾
Series B · Durham, North Carolina · founded 2020 · 6 employees
A next-generation cell cycle control company advancing precision treatments for cancer. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor entering clinical development and has therapeutic targets across many tumor types, including ovarian, breast, and lung cancers.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 25%Talent
top 28%Moat
top 39%Tech
bottom 31%Global
bottom 29%Market
bottom 20%Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series B (Apr 2026)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Apr 2026Series B$5M
- Aug 2025Series B$11.2M
- Mar 2022Series B$30M
Founders & team
Investors
Boxer Capital, RA Capital Management, Eshelman Ventures, Lilly, Pharmacosmos, Cape Fear BioCapital
#3
Series B · Durham, North Carolina · founded 2021 · 3 employees$27.4Mraised▾
Series B · Durham, North Carolina · founded 2021 · 3 employees
Developer of urological devices for post-prostatectomy. It offers VORO urological scaffold a bioresorbable device for urinary incontinence in radical prostatectomy patients. It optimizes and reduces complications associated with surgical treatment.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Feb 2026Series B$12M
- Oct 2025Conventional Debt$12.5M
- Feb 2025Series B$14M
- Sep 2023Series A$4.3M
Founders & team
#4
Series C · Durham, North Carolina · founded 2013 · 133 employees$93.8Mraised▾
Series C · Durham, North Carolina · founded 2013 · 133 employees
Provider of diagnostic products for pediatrics. Its proprietary platform the SEEKER is a microfluidic instrument that enables the high-throughput measurement of enzymatic activity in dried blood specimens of newborn babies. It also has another product the FINDER which is an automated screening solution for critical pediatric tests.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 2.9% of this cohort's audience
Activity: 3 product launches announced in 12 mo
Funding rounds
- Sep 2025Series C$2M
- Feb 2025Grant (prize money)$1.5M
- Apr 2023Grant (prize money)$1.3M
- May 2022Grant (prize money)$2M
Founders & team
Investors
BOE Technology Group, CARB-X, NCBiotech, Duke University, Duke Angel Network, Charleston Angel Partners
Tech stack
BootstrapCloudflareCloudflare Bot ManagementElfsightFlickityFresco
#5
Series C · Durham, North Carolina · founded 2020 · 23 employees$88Mraised▾
Series C · Durham, North Carolina · founded 2020 · 23 employees
Developer of gene therapies for the treatment of ocular diseases. It leverages AAV.SPR, a novel spreading capsid, to evaluate best-in-class gene therapy candidate, ATSN-201, for X-linked retinoschisis a rare pediatric disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 14k LinkedIn followers — 5.8% of this cohort's audience
Activity: 1 partnerships (incl. patients and investigators) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$870.7K
- Mar 2025Series C$150M
- Oct 2023Series B$24.5M
- Dec 2020Series A$55M
Founders & team
Investors
Hatteras Venture Partners, Foundation Fighting Blindness, Sofinnova Investments, Abingworth, Lightstone Ventures, RD Fund
Tech stack
CloudflareCloudflare Bot ManagementCookieyesDocusignGodaddyGoogle Font Api
#6
Series A · Durham, North Carolina · founded 2019 · 10 employees$18.3Mraised▾
Series A · Durham, North Carolina · founded 2019 · 10 employees
Ten63 is a developer of drugs that target undruggable protein targets. The company is developing therapeutics through its platform called COPPER that uses proprietary AI technology and physical models to explore the protein chemical space and screen a large dataset of molecules to identify binding sites.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
top 28%Funding
top 32%Moat
top 35%News
top 44%Global
bottom 39%Tech
bottom 26%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Funding: Raised $18.3M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series A (Feb 2026)
Moat: Editorial + unicorn rating 7/10 · 3 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Principal Scientific Engineer
Funding rounds
- Feb 2026Series A—
- May 2023Series A$15.9M
- Jan 2021Seed$2.1M
- 2019Seed$250K
Founders & team
Investors
Hatteras Venture Partners, Morpheus Ventures, SOSV, Draper, Alexandria, Sigma Group
#7
Series B · Durham, North Carolina · founded 2019 · 72 employees$89Mraised▾
Series B · Durham, North Carolina · founded 2019 · 72 employees
Developer of drug discovery and precision therapy platform for oncology. The company has micro-organ sphere technologies which enable rapid diagnostics, personalized drug screening, and scalable patient-derived models for immuno-oncology drug discovery.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 21%Moat
top 21%Innovation
top 22%Funding
top 26%Talent
bottom 49%Market
bottom 46%Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents · Soonicorn
Innovation: 97 patents (top 19% of patent-holders) · 96 filings since 2022 vs 1 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Apr 2025Series B$19.4M
- Apr 2025Conventional Debt—
- Feb 2025Grant (prize money)$2.4M
- Jul 2022Series A$19M
Founders & team
Investors
Alexandria, EQT, Mubadala, Pear VC, Google Ventures, Duke University
Tech stack
CookieyesCore-JsElementorGoogle WorkspaceHello ElementorJquery
#8
Series B · Durham, North Carolina · founded 2013 · 14 employees$33Mraised▾
Series B · Durham, North Carolina · founded 2013 · 14 employees
Developer of therapeutics for neurodegenerative diseases. Its product includes T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer's disease which treats multiple defects (pathologies) of AD (beta-amyloid pathway and tau pathway) including a likely ‘trigger’ for the disease, insulin, and IGF-resistance.
Funding rounds
- Jul 2025Grant (prize money)$2.5M
- Aug 2023Grant (prize money)$2.3M
- Sep 2022Grant (prize money)$1.5M
- Sep 2022Series B$6M
Founders & team
Investors
NIA, NCBiotech, HHS
#9
Public · Durham, North Carolina · founded 2021 · 14 employees$23.5Mraised▾
Public · Durham, North Carolina · founded 2021 · 14 employees
Developer of gene therapies to treat retinal degenerative diseases. The company is focusing on the development of AAV-based gene therapies to address mutations in genes that cause Leber congenital amaurosis. The company's drug pipeline includes OPGx-001 to target mutations in the LCA5 gene and OPGx-002 for retinal dystrophy.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Patents
top 29%Funding
top 30%Moat
top 32%Innovation
top 34%Talent
top 38%Growth
top 47%Patents: 26 patents matched (strict assignee match) · 26 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding: Raised $23.5M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Grant (prize money) (Aug 2025)
Moat: Editorial + unicorn rating 6/10 · IP moat: 26 patents · 10 curated direct competitors tracked
Funding rounds
- Aug 2025Grant (prize money)$1.7M
- Sep 2024Grant (prize money)$883K
- Jun 2023Seed$4.5M
- Sep 2021Seed$19M
Founders & team
Investors
The Manning Family Foundation, Bios Partners, RD Fund, HHS
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Bot ManagementDocusignFormidable Form
#10
Series A · Durham, North Carolina · founded 2015 · 12 employees$12.9Mraised▾
Series A · Durham, North Carolina · founded 2015 · 12 employees
Deep Blue is involved in developing a hernia mesh to address the high rate of hernia occurrence and recurrence. They have developed T-Line mesh and Anchor Clips that have the potential to reduce hernia occurrence and recurrence.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 885 LinkedIn followers
Funding rounds
- Sep 2025Series A$5.6M
- Jun 2022Series A$7M
- Feb 2021Series A$3.4M
- Jan 2021Series A$1.6M
Investors
NCBiotech, BayMed Venture Partners, HHS, UCSF Rosenman Institute, Kyto Technology & Life Science, Triangle Angel Partners
#11
Funding Raised · Durham, North Carolina · founded 2011 · 2 employees$13.7Mraised▾
Funding Raised · Durham, North Carolina · founded 2011 · 2 employees
Innovating acoustofluidic technologies for research, diagnostics, and therapeutics with social impact. This biotech firm specializes in developing and commercializing acoustofluidic chips and instruments. The core competency lies in rapid prototype development for sample preparation, separation, manipulation of bioparticles, and bioanalysis. The company focuses on creating ready-to-manufacture prototypes with customer validation and collaborating with industry partners on customized product development and integration. The aim is to make a societal impact through innovative acoustofluidic technologies, offering solutions for research, diagnostic, and therapeutic applications.
Funding rounds
- Aug 2025Grant (prize money)$1.7M
- Jun 2024Grant (prize money)$982.9K
- Aug 2019Grant (prize money)$2.7M
- Sep 2018Grant (prize money)$1.5M
Founders & team
Investors
National Science Foundation, HHS, NIH
#12
Seed · Durham, North Carolina · founded 2015 · 29 employees$5.4Mraised▾
Seed · Durham, North Carolina · founded 2015 · 29 employees
Provider of invitro platform for drug testing. The company offers RepliGut a unique, stem cell-derived platform for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Nov 2025Grant (prize money)$1.8M
- Mar 2025Seed$2.1M
- Sep 2023Grant (prize money)$343.3K
- Jul 2023Grant (prize money)$1.8M
Founders & team
Investors
NC IDEA, NCBiotech, VentureSouth, Atlanta Technology Angels, Central Texas Angel Network, Hatteras Venture Partners
Tech stack
Hubspot Cms HubEnvoyHubspotTiny SliderJquery CdnJquery
Funding & investor landscape
$4.8Btotal disclosed funding
134companies funded
809disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Patrick Roberts
Co-Founder & CEO · Incyclix Bio
Jay Strum
Co-Founder · Incyclix Bio
Bruce Choi
Founder & CTO · Levee Medical
Adam Irving
CEO · Levee Medical
Richard West
Co-Founder & CEO · Baebies
Vamsee Pamula
Founder and President · Baebies
Shannon Boye
Founder & Director · Atsena Therapeutics
Patrick Ritschel
Chief Executive Officer · Atsena Therapeutics
Mark Hallen
Co-Founder & CTO · Ten63
Nancy Miller-Rich
Co-Founder · Ten63
Hans Clevers
Co-Founder · Xilis
John Didsbury
Founder and CEO · T3D Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged 5× (33→164 papers), cementing it as the dominant discovery sub-topic in US biotech.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped 3→62 papers, signaling intensifying applied translation of core biology.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled (15→45), reflecting sustained urgency around resistance in US biotechnology research.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Life Sciences companies are there in Durham, United States?
Radar tracks 192 indexable Life Sciences companies headquartered in Durham, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Durham, United States?
The Life Sciences companies in Durham, United States on this list have raised a combined $4.8B in disclosed equity funding across 134 funded companies.
Which is the highest-funded Life Sciences company in Durham, United States?
BioCryst is the highest-funded Life Sciences company in Durham, United States, with $867.3M in disclosed equity funding.
How many Life Sciences companies in Durham, United States are funded?
134 of the 192 Life Sciences companies in Durham, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Durham, United States?
None of the Life Sciences companies in Durham, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Durham, United States Life Sciences companies?
The most active investors in Durham, United States Life Sciences companies on this list include HHS, NCBiotech, Hatteras Venture Partners, NIH, First Flight Venture Center.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.